Sign in Subscribe

chemo

A collection of 72 issues

COMMIT Trial Compares Immunotherapy Alone to Chemo-Plus-Immunotherapy in dMMR Metastatic CRC

Skip to content The CRC Digest ◆ TRIAL DATA COMMIT Trial Compares Immunotherapy Alone to Chemo-Plus-Immunotherapy in dMMR Metastatic CRC The COMMIT trial is a randomized study comparing atezolizumab alone versus mFOLFOX6/bevacizumab/atezolizumab as first-line treatment of deficient DNA mismatch repair metastatic colorectal cancer. (Journal of Clinical Oncology) This content

Comprehensive Review Examines Mechanisms and Management of Irinotecan-Induced Delayed Diarrhea

Skip to content The CRC Digest ♥ LIVING WITH CRC Comprehensive Review Examines Mechanisms and Management of Irinotecan-Induced Delayed Diarrhea A systematic review details how irinotecan's active metabolite SN38 affects the intestinal microenvironment—including flora disruption, immune dysregulation, and barrier impairment—and explores current therapeutic approaches to manage this

HIPEC combined with surgery and systemic therapy may improve outcomes in peritoneal metastases

Skip to content The CRC Digest ▸ TREATMENT HIPEC combined with surgery and systemic therapy may improve outcomes in peritoneal metastases An updated meta-analysis of 12 studies (including 2 randomized controlled trials) encompassing more than 2,700 patients found that hyperthermic intraperitoneal chemotherapy (HIPEC) combined with cytoreductive surgery and systemic therapy

Study Identifies Risk Factors for Serious Intestinal Side Effect With CAPOX Chemotherapy

Skip to content The CRC Digest ♥ LIVING WITH CRC Study Identifies Risk Factors for Serious Intestinal Side Effect With CAPOX Chemotherapy Researchers examined the incidence and risk factors of non-neutropenic enterocolitis—a serious intestinal inflammation—in colorectal cancer patients receiving adjuvant capecitabine and oxaliplatin (CAPOX) chemotherapy. (Clinical Colorectal Cancer) This

Phase Ib FIERCE Study Tests Trifluridine/Tipiracil With Radiation Before Rectal Cancer Surgery

Skip to content The CRC Digest ◆ TRIAL DATA Phase Ib FIERCE Study Tests Trifluridine/Tipiracil With Radiation Before Rectal Cancer Surgery A phase Ib trial evaluated the safety of combining trifluridine/tipiracil chemotherapy with radiation therapy before surgery in patients with resectable stage II/III rectal cancer. (Clinical Colorectal Cancer)

Chemotherapy rechallenge shows activity in late-line metastatic disease

Skip to content The CRC Digest ◆ TRIAL DATA Chemotherapy rechallenge shows activity in late-line metastatic disease A phase II trial found that patients with refractory metastatic colorectal cancer who had previously responded to a regimen for at least 4 months could benefit from rechallenge with the same chemotherapy, with or

Disrupting KRAS-AGO2 interaction may sensitize KRAS-mutant CRC to therapy

Skip to content The CRC Digest Disrupting KRAS-AGO2 interaction may sensitize KRAS-mutant CRC to therapy Preclinical research developed peptide-gold nanoparticles that disrupt the interaction between mutated KRAS and AGO2, potentially sensitizing KRAS-mutated colorectal cancer to chemo-immunotherapy. (Apoptosis) This content is informational only and does not constitute medical advice. Always consult

Study identifies risk factors for irinotecan liver toxicity

Skip to content The CRC Digest ♥ LIVING WITH CRC Study identifies risk factors for irinotecan liver toxicity A retrospective study of 229 cancer patients receiving irinotecan chemotherapy identified key risk factors for hepatotoxicity, which could help clinicians monitor and manage this side effect more effectively. (Frontiers in Oncology) This content

Sotorasib plus panitumumab and FOLFIRI shows activity in KRAS G12C-mutated metastatic CRC

Skip to content The CRC Digest ◆ TRIAL DATA Sotorasib plus panitumumab and FOLFIRI shows activity in KRAS G12C-mutated metastatic CRC In the phase Ib CodeBreaK 101 trial, the triple combination of sotorasib (a KRAS G12C inhibitor), panitumumab, and FOLFIRI chemotherapy was tested in previously treated patients with KRAS G12C-mutated metastatic

FOLFOXIRI Plus Panitumumab as First-Line Therapy for Left-Sided RAS Wild-Type Metastatic CRC

Skip to content The CRC Digest ▸ TREATMENT FOLFOXIRI Plus Panitumumab as First-Line Therapy for Left-Sided RAS Wild-Type Metastatic CRC A multicenter trial tested modified FOLFOXIRI combined with panitumumab every two weeks in patients with left-sided, RAS wild-type metastatic colorectal cancer. (The Oncologist) This content is informational only and does not